特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
943535

結核治療薬市場:療法、疾患タイプ、流通チャネル、地域別の分析、市場規模、シェア、動向、および予測(2020年~2026年)

Tuberculosis Drugs Market, By Therapy, By Disease Type, By Distribution Channel, and By Geography - Analysis, Size, Share, Trends, & Forecast from 2020-2026

出版日: | 発行: AnalystView Market Insights | ページ情報: 英文 198 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.58円
結核治療薬市場:療法、疾患タイプ、流通チャネル、地域別の分析、市場規模、シェア、動向、および予測(2020年~2026年)
出版日: 2020年06月01日
発行: AnalystView Market Insights
ページ情報: 英文 198 Pages
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の結核治療薬市場は、2019年に10億4,580万米ドルとなりました。同市場は、2020年から2026年の予測期間中に5.2%のCAGRで成長すると見込まれています。同市場の主な成長要因には、患者数の増加、政府の前向きな支援による疾患に関する意識の拡大などが挙げられます。世界保健機関(WHO)2019年のレポートによると、世界において毎年1,000万人以上が結核を罹っており、世界の主な死因の10位以内に入っています。したがって、結核治療薬の需要は予測期間にわたって増加する見通しです。さらに、結核のアライアンス、WHO、ユニセフなどの国際組織からの協力と支援により、疾病による負担を軽減し、潜在的な医療ニーズに対処することで、今後数年間の市場成長が促進されると予測されています。

当レポートは世界の結核治療薬市場について調査しており、市場機会や動向、成長および抑制要因、療法・疾患タイプ・流通チャネル・地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 市場概要

第2章 エグゼクティブサマリー

  • 市場内訳
    • 療法別
    • 疾患タイプ別
    • 流通チャネル別
    • 地域別
  • 競合考察

第3章 主要市場動向

  • 市場成長要因
  • 市場抑制要因
  • 市場機会
  • 市場の将来動向

第4章 業界調査

  • ポーターのファイブフォース分析
  • マーケティング戦略分析
  • 成長見通しマッピング
  • 規制枠組み分析
  • COVID-19影響分析

第5章 市場情勢

  • 市場シェア分析
  • 主な革新者
  • 主要メーカー別の内訳データ
    • 既存企業分析
    • 新興企業分析

第6章 市場分析:療法別

  • 概観
  • ファーストラインセラピー
  • セカンドラインセラピー
  • 併用療法

第7章 市場分析:疾患タイプ別

  • 概観
  • 潜在性結核
  • 活動性結核
  • 薬剤耐性結核

第8章 市場分析:流通チャネル別

  • 概観
  • 病院薬局
  • 小売薬局
  • オンライン薬局

第9章 市場分析:地域別

  • イントロダクション
    • セグメントシェア分析
  • 北米
  • 欧州
  • アジア太平洋地域
  • ラテンアメリカ
  • 中東・アフリカ

第10章 ベンダーの分析

  • Cadila Healthcare Ltd
  • Lupin Limited
  • AstraZeneca plc
  • Johnson & Johnson
  • Bayer AG
  • Pfizer, Inc.
  • Novartis AG
  • Macleods Pharmaceuticals
  • 大塚製薬株式会社

第11章 アナリストの見解

第12章 付録

図表

List of Tables

  • TABLE List of data sources
  • TABLE Market drivers; Impact Analysis
  • TABLE Market restraints; Impact Analysis
  • TABLE tuberculosis drugs market: Therapy Snapshot (2018)
  • TABLE Segment Dashboard; Definition and Scope, by Therapy
  • TABLE Global tuberculosis drugs market, by Therapy 2015-2026 (USD Million)
  • TABLE Tuberculosis drugs market: Disease Type Snapshot (2018)
  • TABLE Segment Dashboard; Definition and Scope, by Disease Type

Table Global Tuberculosis Drugs Market, By Disease Type 2015-2026 (Usd Million)

Table Tuberculosis Drugs Market: Distribution Channel Snapshot (2018)

Table Segment Dashboard; Definition And Scope, By Distribution Channel

Table Global Tuberculosis Drugs Market, By Distribution Channel 2015-2026 (Usd Million)

Table Tuberculosis Drugs Market: Regional Snapshot (2018)

Table Segment Dashboard; Definition And Scope, By Region

Table Global Tuberculosis Drugs Market, By Region 2015-2026 (Usd Million)

Table North America Tuberculosis Drugs Market, By Country, 2015-2026 (Usd Million)

Table North America Tuberculosis Drugs Market, By Therapy, 2015-2026 (Usd Million)

Table North America Tuberculosis Drugs Market, By Disease Type, 2015-2026 (Usd Million)

Table North America Tuberculosis Drugs Market, By Distribution Channel, 2015-2026 (Usd Million)

Table Europe Tuberculosis Drugs Market, By Country, 2015-2026 (Usd Million)

Table Europe Tuberculosis Drugs Market, By Therapy, 2015-2026 (Usd Million)

Table Europe Tuberculosis Drugs Market, By Disease Type, 2015-2026 (Usd Million)

Table Europe Tuberculosis Drugs Market, By Distribution Channel, 2015-2026 (Usd Million)

FTable Asia Pacific Tuberculosis Drugs Market, By Country, 2015-2026 (Usd Million)

Table Asia Pacific Tuberculosis Drugs Market, By Therapy, 2015-2026 (Usd Million)

Table Asia Pacific Tuberculosis Drugs Market, By Distribution Channel, 2015-2026 (Usd Million)

Table Asia Pacific Tuberculosis Drugs Market, By Disease Type, 2015-2026 (Usd Million)

Table Latin America Tuberculosis Drugs Market, By Country, 2015-2026 (Usd Million)

Table Latin America Tuberculosis Drugs Market, By Distribution Channel, 2015-2026 (Usd Million)

Table Latin America Tuberculosis Drugs Market, By Therapy, 2015-2026 (Usd Million)

Table Latin America Tuberculosis Drugs Market, By Disease Type, 2015-2026 (Usd Million)

  • TABLE Middle East And Africa Tuberculosis Drugs Market, By Country, 2015-2026 (USD Million)

Table Middle East And Africa Tuberculosis Drugs Market, By Distribution Channel, 2015-2026 (Usd Million)

Table Middle East And Africa Tuberculosis Drugs Market, By Therapy, 2015-2026 (Usd Million)

Table Middle East And Africa Tuberculosis Drugs Market, By Disease Type, 2015-2026 (Usd Million)

List of Figures

  • FIGURE Tuberculosis Drugs market segmentation
  • FIGURE Market research methodology
  • FIGURE Value chain analysis
  • FIGURE Porter's Five Forces Analysis
  • FIGURE Market Attractiveness Analysis
  • FIGURE COVID-19 Impact Analysis
  • FIGURE Pre & Post COVID-19 Impact Comparision Study
  • FIGURE Competitive Landscape; Key company market share analysis, 2018
  • FIGURE Therapy segment market share analysis, 2019 & 2026
  • FIGURE First Line Therapy segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Isoniazid market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Pyrazinamide market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Rifampicin market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Ethambutol market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Streptomycin market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Second Line Therapy segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Fluoroquinolones market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Injectable Antituberculosis Drugs market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Combination Therapy market size forecast and trend analysis, 2015 to 2026 (USD Million
  • FIGURE Disease Type segment market share analysis, 2019 & 2026
  • FIGURE Disease Type segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Latent Tuberculosis market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Active Tuberculosis market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Drug-Resistant Tuberculosis market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Distribution Channel segment market share analysis, 2019 & 2026
  • FIGURE Distribution Channel segment market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Hospital Pharmacy market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Retail Pharmacy market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Online Pharmacy market size forecast and trend analysis, 2015 to 2026 (USD Million)
  • FIGURE Regional segment market share analysis, 2019 & 2026
  • FIGURE Regional segment market size forecast and trend analysis, 2015 to 2026 (USD Million)

Figure North America Tuberculosis Drugs Market Share And Leading Players, 2018

Figure Europe Tuberculosis Drugs Market Share And Leading Players, 2018

Figure Asia Pacific Tuberculosis Drugs Market Share And Leading Players, 2018

Figure Latin America Tuberculosis Drugs Market Share And Leading Players, 2018

Figure Middle East And Africa Tuberculosis Drugs Market Share And Leading Players, 2018

Figure North America Market Share Analysis By Country, 2018

Figure U.S. Tuberculosis Drugs Market Size, Forecast And Trend Analysis, 2015 To 2026 (Usd Million)

Figure Canada Tuberculosis Drugs Market Size, Forecast And Trend Analysis, 2015 To 2026 (Usd Million)

Figure Europe Tuberculosis Drugs Market Share Analysis By Country, 2018

Figure Germany Tuberculosis Drugs Market Size, Forecast And Trend Analysis, 2015 To 2026 (USD Million)

Figure Spain Tuberculosis Drugs Market Size, Forecast And Trend Analysis, 2015 To 2026 (Usd Million)

Figure Italy Tuberculosis Drugs Market Size, Forecast And Trend Analysis, 2015 To 2026 (Usd Million)

Figure Uk Tuberculosis Drugs Market Size, Forecast And Trend Analysis, 2015 To 2026 (Usd Million)

Figure France Tuberculosis Drugs Market Size, Forecast And Trend Analysis, 2015 To 2026 (Usd Million)

Figure Rest Of The Europe Tuberculosis Drugs Market Size, Forecast And Trend Analysis, 2015 To 2026 (Usd Million)

Figure Asia Pacific Tuberculosis Drugs Market Share Analysis By Country, 2018

Figure India Tuberculosis Drugs Market Size, Forecast And Trend Analysis, 2015 To 2026 (Usd Million)

Figure China Tuberculosis Drugs Market Size, Forecast And Trend Analysis, 2015 To 2026 (Usd Million)

Figure Japan Tuberculosis Drugs Market Size, Forecast And Trend Analysis, 2015 To 2026 (Usd Million)

Figure South Korea Tuberculosis Drugs Market Size, Forecast And Trend Analysis, 2015 To 2026 (Usd Million)

Figure Singapore Tuberculosis Drugs Market Size, Forecast And Trend Analysis, 2015 To 2026 (Usd Million)

Figure Rest Of Apac Tuberculosis Drugs Market Size, Forecast And Trend Analysis, 2015 To 2026 (Usd Million)

Figure Latin America Tuberculosis Drugs Market Size, Forecast And Trend Analysis, 2015 To 2026 (Usd Million)

Figure Latin America Tuberculosis Drugs Market Share Analysis By Country, 2018

Figure Brazil Tuberculosis Drugs Market Size, Forecast And Trend Analysis, 2015 To 2026 (Usd Million)

  • FIGURE Mexico Tuberculosis Drugs Market size, forecast and trend analysis, 2015 to 2026 (USD Million)

Figure Argentina Tuberculosis Drugs Market Size, Forecast And Trend Analysis, 2015 To 2026 (Usd Million)

Figure Rest Of Latam Tuberculosis Drugs Market Size, Forecast And Trend Analysis, 2015 To 2026 (Usd Million)

Figure Middle East And Africa Tuberculosis Drugs Market Size, Forecast And Trend Analysis, 2015 To 2026 (Usd Million)

Figure Middle East And Africa Tuberculosis Drugs Market Share Analysis By Country, 2018

Figure Saudi Arabia Tuberculosis Drugs Market Size, Forecast And Trend Analysis, 2015 To 2026 (Usd Million)

Figure United Arab Emirates Tuberculosis Drugs Market Size, Forecast And Trend Analysis, 2015 To 2026 (Usd Million)

目次

Title:
Tuberculosis Drugs Market, By Therapy (First Line Therapy, Second Line Therapy, and Combination Therapy), By Disease Type (Active Tuberculosis, Latent Tuberculosis, and Drug-Resistant Tuberculosis), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy, and Online Pharmacy), and By Geography (EU, NA, APAC, LATAM, and MEA) - Analysis, Size, Share, Trends, & Forecast from 2020-2026.

Report Highlight

The tuberculosis drugs market was valued at USD 1,045.8 million by 2019, growing with 5.2% CAGR during the forecast period, 2020-2026.

Report Highlight

Tuberculosis or TB is a contagious bacterial infection (caused by bacteria called "Mycobacterium Tuberculosis") that usually attacks the patient's lungs. TB in general terms is a key health concern worldwide. In 2018, according to a report by the World Health Organization (WHO) around 10 million people were affected by tuberculosis. These cases were identified from all age groups. Thus, WHO identifies TB as the 9th leading cause of patient's death. Tuberculosis disease is caused due to infection of Mycobacterium tuberculosis bacteria to the human lungs.

Market Dynamics

The rising number of patients suffering from tuberculosis coupled with favorable government support on spreading awareness regarding this disease is driving the industry growth. According to the World Health Organization (WHO) 2019 report, more than 10 million people are affected with tuberculosis condition every year, worldwide. The condition is a leading cause of death from a single infectious agent, accounting for one of the top 10 causes of death globally. Thus, the demand for TB therapeutics is set to increase over the forecast period, driving the market growth. Additionally, collaborations and assistance from international organizations including TB Alliance, WHO, and UNICEF to lower the burden caused due to the disease and addressing unmet medical needs, which is estimated to fuel market growth in the coming years. Also, the introduction of new anti-TB drug regimens, improvement in diagnostic tests in low-resource settings, such as drug susceptibility testing are some of the potential driving factors for the market growth. Furthermore, recommendations in favor of developing shorter regimens and the use of fourth-generation fluoroquinolones for MDR-TB are considered to be leading to changes in the TB drug market.

Despite such growth inducing factors, drug shortage especially in developing countries is estimated to create challenges for the growth of the market. Nonetheless, the introduction of a Multi-Drug Resistant Tuberculosis Program is likely to offer several opportunities for growth in the coming years. In addition, the high cost associated with the treatment of second-line TB will hamper the market growth. For example, as per the U.S. Department of Health & Human Services' data, the average direct cost for the treatment of drug-susceptible TB would be around USD 16,000, USD 150,000 for MDR-TB, and USD 510,000 for the treatment of extensively drug-resistant TB (XDR-TB).

Therapy Takeaway

By therapy, tuberculosis drugs market is segmented into first-line (serve the Drug Susceptible or Sensitive (DS) TB patient), second-line (serve the Drug Resistant (DR) TB patient), and combination therapy. Among which, second-line TB therapy accounted for the highest revenue share as the cost of this therapy, particularly for Active TB is on the decline. The second line therapy is further segmented into injectable anti-tuberculosis drugs and fluoroquinolones. Some of the examples of the second-line category include moxifloxacin, levofloxacin, Bedaquiline, Linezolid, and Delamanid. Also, in 2019, Pretomanid is newly introduced second-line products, indicated for the treatment of drug-resistant TB.

On the other side, first-line therapy follows an upward growth with the developing countries are witnessing an increase in DS-TB incidence in both ATB and LTB forms. The segment is further segmented into rifampicin, ethambutol, isoniazid, pyrazinamide, and streptomycin.

Disease Type Takeaways

By disease type, the global tuberculosis drug industry is segmented into active tuberculosis, latent tuberculosis, and drug-resistant tuberculosis. Of these, the active tuberculosis segment held a substantial share owing to a rising number of active TB cases. According to the Centers for Disease Control and Prevention (CDC), more than 10 million people globally develop active TB on an annual basis. The ATB form involves symptomatic expression of Mycobacterium tuberculosis infection which is detected easily due to perceivable symptoms. On the contrary, latent tuberculosis is projected to grow with promising CAGR over the study period. The World Health Organization (WHO) defined latent TB as a state of the persistent immune response which is stimulated by M. tuberculosis antigens without clinically manifested active TB.

Distribution Channel Takeaways

Based on the distribution channel segment, the market is bifurcated into retail pharmacy, hospital pharmacy, and online pharmacy. Of these, the market is dominated by the hospital segment as the demand for medicines is increased due to a substantial rise in patients globally, particularly in the underdeveloped countries. Whereas, the online category is projected to grow with the fastest growth rate during the study period.

Regional Takeaway

Regionally, the overall market for tuberculosis drugs is divided into North America, Middle East & Africa, Asia Pacific, Latin America, and Europe. Of these, Asia Pacific dominated the market in the year 2019 owing to a higher prevalence of the disease in the region. According to the WHO, around one-third of the patients of the world are from the Asia Pacific region, which is creating a robust need for better treatment options.

Additionally, the Middle East & Africa region is estimated to witness the fastest growth of the market owing to an increase in patient pool coupled with the availability of treatments in the region. Furthermore, developed regions such as North America and Europe accounted for the significant revenue share. It is noted that the majority of the TB cases in these regions registered from foreign-born people who are entering these countries as well as those exposed to TB due to travel to regions.

COVID-19 Impact

The tuberculosis drug market is witnessing a few adverse effects due to the outbreak of COVID-19 globally. Patients are experiencing the unavailability of treatments and drugs due to lockdown in major areas of the world. Change in the role of hospitals treating tuberculosis is also a major concern, as there is an inevitable interruption in diagnostic, which creates risk for other house members, as they are more prone to the disease. The outbreak also results in lower enthusiasm among patients regarding regular check-ups and treatments. Such factors are witnessed to impact adversely from the past few months and may continue until the situation becomes normal regarding COVID.

Key Vendor Takeaway

The key players operating in the global tuberculosis drugs market include Pfizer, Inc., Novartis AG, Macleods Pharmaceuticals, Bayer AG, Cadila Healthcare, Lupin Limited, AstraZeneca plc, Johnson & Johnson, and Otsuka Pharmaceutical Co. Ltd.

These companies are looking for strategic mergers and acquisitions to expand their customer reach. Additionally, the companies are trying to enter into partnerships with several healthcare organizations for improving the drug and treatments. Further, the approvals of newer drugs and treatments by the US Food and Drug Administration (FDA) are majorly benefiting the players. For instance, in August 2019, the U.S. FDA approved a novel compound for highly drug-resistant forms of TB named "Pretomanid". This molecule was developed by the non-profit TB Alliance and approved under the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD pathway).

The market size and forecast for each segment and sub-segments has been considered as below:

Historical Year - 2015 to2018

Base Year - 2019

Estimated Year - 2020

Projected Year - 2026

TARGET AUDIENCE

Traders, Distributors, and Suppliers

Manufacturers

Government and Regional Agencies

Research Organizations

Consultants

Distributors

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

TUBERCULOSIS DRUGS MARKET KEY PLAYERS

AstraZeneca plc

Johnson & Johnson

Bayer AG

Cadila Healthcare Ltd

Lupin Limited

Pfizer, Inc.

Novartis AG

Macleods Pharmaceuticals

Otsuka Pharmaceutical Co., Ltd.

Other players

TUBERCULOSIS DRUGS MARKET, BY THERAPY

First-Line Therapy

Isoniazid

Pyrazinamide

Rifampicin

Ethambutol

Streptomycin

Second-Line Therapy

Fluoroquinolones

Injectable Anti-tuberculosis Drugs

Combination Therapy

TUBERCULOSIS DRUGS MARKET, BY DISEASE TYPE

Latent Tuberculosis

Active Tuberculosis

Drug-Resistant Tuberculosis

TUBERCULOSIS DRUGS MARKET, BY DISTRIBUTION CHANNEL

Hospital Pharmacy

Retail Pharmacy

Online Pharmacy

TUBERCULOSIS DRUGS MARKET, BY REGION

North America

The U.S.

Canada

Europe

Germany

France

Italy

Spain

United Kingdom

Rest of Europe

Asia Pacific

India

China

South Korea

Japan

Singapore

Rest of APAC

Latin America

Brazil

Mexico

Argentina

Rest of LATAM

The Middle East and Africa

Saudi Arabia

United Arab Emirates

Rest of MEA

TABLE OF CONTENT

1. TUBERCULOSIS DRUGS MARKET OVERVIEW

  • 1.1. Study Scope
  • 1.2. Assumption and Methodology

2. EXECUTIVE SUMMARY

  • 2.1. Market Snippet
    • 2.1.1. Market Snippet by Therapy
    • 2.1.2. Market Snippet by Disease Type
    • 2.1.3. Market Snippet by Distribution Channel
    • 2.1.4. Market Snippet by Region
  • 2.2. Competitive Insights

3. TUBERCULOSIS DRUGS KEY MARKET TRENDS

  • 3.1. Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Future Trends

4. TUBERCULOSIS DRUGS INDUSTRY STUDY

  • 4.1. Porter's Five Forces Analysis
  • 4.2. Marketing Strategy Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis
  • 4.5. COVID-19 Impact Analysis
    • 4.5.1. Pre-COVID-19 Impact Analysis
    • 4.5.2. Post-COVID-19 Impact Analysis

5. TUBERCULOSIS DRUGS MARKET LANDSCAPE

  • 5.1. Market Share Analysis
  • 5.2. Key Innovators
  • 5.3. Breakdown Data, by Key manufacturer
    • 5.3.1. Established Player Analysis
    • 5.3.2. Emerging Player Analysis

6. TUBERCULOSIS DRUGS MARKET - BY THERAPY

  • 6.1. Overview
    • 6.1.1. Segment Share Analysis, By Therapy, 2019 & 2026 (%)
  • 6.2. First Line Therapy
    • 6.2.1. Overview
    • 6.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 6.2.3. Rifampicin
      • 6.2.3.1. Overview
      • 6.2.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 6.2.4. Ethambutol
      • 6.2.4.1. Overview
      • 6.2.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 6.2.5. Isoniazid
      • 6.2.5.1. Overview
      • 6.2.5.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 6.2.6. Pyrazinamide
      • 6.2.6.1. Overview
      • 6.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 6.2.7. Streptomycin
      • 6.2.7.1. Overview
      • 6.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 6.3. Second Line Therapy
    • 6.3.1. Overview
    • 6.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 6.3.3. Injectable Anti-Tuberculosis Drugs
      • 6.3.3.1. Overview
      • 6.3.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 6.3.4. Fluoroquinolones
      • 6.3.4.1. Overview
      • 6.3.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 6.4. Combination Therapy
    • 6.4.1. Overview
    • 6.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

7. TUBERCULOSIS DRUGS MARKET - BY DISEASE TYPE

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Disease Type, 2019 & 2026 (%)
  • 7.2. Latent Tuberculosis
    • 7.2.1. Overview
    • 7.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 7.3. Active Tuberculosis
    • 7.3.1. Overview
    • 7.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 7.4. Drug-Resistant Tuberculosis
    • 7.4.1. Overview
    • 7.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

8. TUBERCULOSIS DRUGS MARKET - BY DISTRIBUTION CHANNEL

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Distribution Channel, 2019 & 2026 (%)
  • 8.2. Hospital Pharmacy
    • 8.2.1. Overview
    • 8.2.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 8.3. Retail Pharmacy
    • 8.3.1. Overview
    • 8.3.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 8.4. Online Pharmacy
    • 8.4.1. Overview
    • 8.4.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

9. TUBERCULOSIS DRUGS MARKET- BY GEOGRAPHY

  • 9.1. Introduction
    • 9.1.1. Segment Share Analysis, By Region, 2019 & 2026 (%)
  • 9.2. North America
    • 9.2.1. Overview
    • 9.2.2. Key Manufacturers in North America
    • 9.2.3. North America Market Size and Forecast, By Country, 2015 - 2026 (US$ Million)
    • 9.2.4. North America Market Size and Forecast, By Therapy, 2015 - 2026 (US$ Million)
    • 9.2.5. North America Market Size and Forecast, By Disease Types, 2015 - 2026 (US$ Million)
    • 9.2.6. North America Market Size and Forecast, By Distribution Channel, 2015 - 2026 (US$ Million)
    • 9.2.7. U.S.
      • 9.2.7.1. Overview
      • 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 9.2.8. Canada
      • 9.2.8.1. Overview
      • 9.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 9.3. Europe
    • 9.3.1. Overview
    • 9.3.2. Key Manufacturers in Europe
    • 9.3.3. Europe Market Size and Forecast, By Country, 2015 - 2026 (US$ Million)
    • 9.3.4. Europe Market Size and Forecast, By Therapy, 2015 - 2026 (US$ Million)
    • 9.3.5. Europe Market Size and Forecast, By Disease Type, 2015 - 2026 (US$ Million)
    • 9.3.6. Europe Market Size and Forecast, By Distribution Channel, 2015 - 2026 (US$ Million)
    • 9.3.7. Germany
      • 9.3.7.1. Overview
      • 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 9.3.8. Italy
      • 9.3.8.1. Overview
      • 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 9.3.9. United Kingdom
      • 9.3.9.1. Overview
      • 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 9.3.10. France
      • 9.3.10.1. Overview
      • 9.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 9.3.11. Rest of Europe
      • 9.3.11.1. Overview
      • 9.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 9.4. Asia Pacific (APAC)
    • 9.4.1. Overview
    • 9.4.2. Key Manufacturers in Asia Pacific
    • 9.4.3. Asia Pacific Market Size and Forecast, By Country, 2015 - 2026 (US$ Million)
    • 9.4.4. Asia Pacific Market Size and Forecast, By Therapy, 2015 - 2026 (US$ Million)
    • 9.4.5. Asia Pacific Market Size and Forecast, By Disease Type, 2015 - 2026 (US$ Million)
    • 9.4.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2015 - 2026 (US$ Million)
    • 9.4.7. India
      • 9.4.7.1. Overview
      • 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 9.4.8. China
      • 9.4.8.1. Overview
      • 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 9.4.9. Japan
      • 9.4.9.1. Overview
      • 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 9.4.10. South Korea
      • 9.4.10.1. Overview
      • 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 9.4.11. Rest of APAC
      • 9.4.11.1. Overview
      • 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 9.5. Latin America
    • 9.5.1. Overview
    • 9.5.2. Key Manufacturers in Latin America
    • 9.5.3. Latin America Market Size and Forecast, By Country, 2015 - 2026 (US$ Million)
    • 9.5.4. Latin America Market Size and Forecast, By Therapy, 2015 - 2026 (US$ Million)
    • 9.5.5. Asia Pacific Market Size and Forecast, By Disease Type, 2015 - 2026 (US$ Million)
    • 9.5.6. Asia Pacific Market Size and Forecast, By Distribution Channel, 2015 - 2026 (US$ Million)
    • 9.5.7. Brazil
      • 9.5.7.1. Overview
      • 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 9.5.8. Mexico
      • 9.5.8.1. Overview
      • 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 9.5.9. Argentina
      • 9.5.9.1. Overview
      • 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 9.5.10. Rest of LATAM
      • 9.5.10.1. Overview
      • 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
  • 9.6. Middle East and Africa
    • 9.6.1. Overview
    • 9.6.2. Key Manufacturers in Middle East and Africa
    • 9.6.3. Middle East and Africa Market Size and Forecast, By Country, 2015 - 2026 (US$ Million)
    • 9.6.4. Middle East and Africa Market Size and Forecast, By Therapy, 2015 - 2026 (US$ Million)
    • 9.6.5. Middle East and Africa Market Size and Forecast, By Disease Type, 2015 - 2026 (US$ Million)
    • 9.6.6. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2015 - 2026 (US$ Million)
    • 9.6.7. Saudi Arabia
      • 9.6.7.1. Overview
      • 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)
    • 9.6.8. United Arab Emirates
      • 9.6.8.1. Overview
      • 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2015 - 2026, (US$ Million)

10. KEY VENDOR ANALYSIS

  • 10.1. Cadila Healthcare Ltd
    • 10.1.1. Company Snapshot
    • 10.1.2. Financial Performance
    • 10.1.3. Product Benchmarking
    • 10.1.4. Strategic Initiatives
  • 10.2. Lupin Limited
  • 10.3. AstraZeneca plc
  • 10.4. Johnson & Johnson
  • 10.5. Bayer AG
  • 10.6. Pfizer, Inc.
  • 10.7. Novartis AG
  • 10.8. Macleods Pharmaceuticals
  • 10.9. Otsuka Pharmaceutical Co., Ltd.

11. 360 DEGREE ANALYSTVIEW

12. APPENDIX

  • 12.1. Research Methodology
  • 12.2. References
  • 12.3. Abbreviations
  • 12.4. Disclaimer
  • 12.5. Contact Us
株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.